Université Paris Cité, IAME, INSERM, Paris, France.
Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.
Clin Pharmacol Ther. 2024 Jan;115(1):86-94. doi: 10.1002/cpt.3069. Epub 2023 Oct 20.
Although anti-severe acute respiratory syndrome-coronavirus 2 antibody kinetics have been described in large populations of vaccinated individuals, we still poorly understand how they evolve during a natural infection and how this impacts viral clearance. For that purpose, we analyzed the kinetics of both viral load and neutralizing antibody levels in a prospective cohort of individuals during acute infection with alpha variant. Using a mathematical model, we show that the progressive increase in neutralizing antibodies leads to a shortening of the half-life of both infected cells and infectious viral particles. We estimated that the neutralizing activity reached 90% of its maximal level within 11 days after symptom onset and could reduce the half-life of both infected cells and circulating virus by a 6-fold factor, thus playing a key role to achieve rapid viral clearance. Using this model, we conducted a simulation study to predict in a more general context the protection conferred by pre-existing neutralization titers, due to either vaccination or prior infection. We predicted that a neutralizing activity, as measured by 50% effective dose > 10 , could reduce by 46% the risk of having viral load detectable by standard polymerase chain reaction assays and by 98% the risk of having viral load above the threshold of infectiousness. Our model shows that neutralizing activity could be used to define correlates of protection against infection and transmission.
虽然在接种疫苗的大量人群中已经描述了抗严重急性呼吸综合征冠状病毒 2 抗体的动力学,但我们仍然不太了解它们在自然感染过程中是如何演变的,以及这如何影响病毒清除。为此,我们在急性感染阿尔法变异株的前瞻性队列中分析了个体的病毒载量和中和抗体水平的动力学。我们使用数学模型表明,中和抗体的逐渐增加导致感染细胞和传染性病毒颗粒的半衰期缩短。我们估计,中和活性在症状出现后 11 天内达到最大水平的 90%,并可使感染细胞和循环病毒的半衰期降低 6 倍,从而在实现快速病毒清除方面发挥关键作用。使用该模型,我们进行了一项模拟研究,以更普遍的背景预测由于接种疫苗或先前感染而产生的预先存在的中和滴度所带来的保护作用。我们预测,中和活性(以 50%有效剂量>10 来衡量)可使标准聚合酶链反应检测到的病毒载量的风险降低 46%,并使具有传染性的病毒载量的风险降低 98%。我们的模型表明,中和活性可用于定义针对感染和传播的保护相关因素。